Uniqure NV
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. Th… Read more
Uniqure NV (QURE) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.072x
Based on the latest financial reports, Uniqure NV (QURE) has a cash flow conversion efficiency ratio of -0.072x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.40 Million) by net assets ($228.75 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Uniqure NV - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Uniqure NV's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Uniqure NV Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Uniqure NV ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
UroGen Pharma Ltd
NASDAQ:URGN
|
0.363x |
|
Gujarat Gas Limited
NSE:GUJGASLTD
|
0.117x |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
0.014x |
|
Legend Holdings Corporation
PINK:LGNRF
|
-0.003x |
|
Esquire Financial Holdings Inc
NASDAQ:ESQ
|
0.058x |
|
CytomX Therapeutics Inc
NASDAQ:CTMX
|
-0.145x |
|
Astria Therapeutics Inc
NASDAQ:ATXS
|
-0.138x |
|
Shenzhen Feima International Supply Chain Co Ltd
SHE:002210
|
0.042x |
Annual Cash Flow Conversion Efficiency for Uniqure NV (2011–2024)
The table below shows the annual cash flow conversion efficiency of Uniqure NV from 2011 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-6.75 Million | $-182.73 Million | 27.063x | +3951.28% |
| 2023-12-31 | $207.67 Million | $-145.93 Million | -0.703x | -130.59% |
| 2022-12-31 | $476.01 Million | $-145.06 Million | -0.305x | -163.05% |
| 2021-12-31 | $595.78 Million | $287.96 Million | 0.483x | +187.44% |
| 2020-12-31 | $243.91 Million | $-134.83 Million | -0.553x | -80.96% |
| 2019-12-31 | $323.06 Million | $-98.68 Million | -0.305x | +27.85% |
| 2018-12-31 | $179.61 Million | $-76.04 Million | -0.423x | +40.75% |
| 2017-12-31 | $89.94 Million | $-64.27 Million | -0.715x | +37.02% |
| 2016-12-31 | $63.63 Million | $-72.19 Million | -1.134x | -889.30% |
| 2015-12-31 | $130.63 Million | $18.78 Million | 0.144x | +124.36% |
| 2014-12-31 | $52.39 Million | $-30.92 Million | -0.590x | +20.61% |
| 2013-12-31 | $7.68 Million | $-5.71 Million | -0.743x | -102.95% |
| 2012-12-31 | $-592.48K | $-14.91 Million | 25.172x | +290.73% |
| 2011-12-31 | $-3.36 Million | $-21.65 Million | 6.442x | -- |